Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 197

Similar articles for PubMed (Select 17048425)

1.

Asian outpatients with schizophrenia: a double-blind randomized comparison of quality of life and clinical outcomes for patients treated with olanzapine or haloperidol.

Kongsakon R, Trinidad-Oñate P, Chaudhry HR, Raza SB, Leynes CR, Khan IU, Ismail HC, Chan B, Ignacio JC, Rodriguez SC, Lowry AJ, Brnabic AJ, Buenaventura R.

J Med Assoc Thai. 2006 Aug;89(8):1157-70.

PMID:
17048425
2.
3.

Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.

Dossenbach M, Pecenak J, Szulc A, Irimia V, Anders M, Logozar-Perkovic D, Peciukaitiene D, Kotler M, Smulevich AB, West TM, Lowry AJ, Treuer T.

J Clin Psychiatry. 2008 Dec;69(12):1901-15. Epub 2008 Sep 9.

PMID:
19012820
4.

The relationship between quality of life and clinical efficacy from a randomized trial comparing olanzapine and ziprasidone.

Phillips GA, Van Brunt DL, Roychowdhury SM, Xu W, Naber D.

J Clin Psychiatry. 2006 Sep;67(9):1397-403.

PMID:
17017826
5.

A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia.

Breier A, Meehan K, Birkett M, David S, Ferchland I, Sutton V, Taylor CC, Palmer R, Dossenbach M, Kiesler G, Brook S, Wright P.

Arch Gen Psychiatry. 2002 May;59(5):441-8.

PMID:
11982448
6.

Olanzapine vs haloperidol in geriatric schizophrenia: analysis of data from a double-blind controlled trial.

Kennedy JS, Jeste D, Kaiser CJ, Golshan S, Maguire GA, Tollefson G, Sanger T, Bymaster FP, Kinon BJ, Dossenbach M, Gilmore JA, Breier A.

Int J Geriatr Psychiatry. 2003 Nov;18(11):1013-20.

PMID:
14618553
7.

Functional outcomes in schizophrenia: a comparison of olanzapine and haloperidol in a European sample.

Hamilton SH, Edgell ET, Revicki DA, Breier A.

Int Clin Psychopharmacol. 2000 Sep;15(5):245-55.

PMID:
10993126
8.

[Safety and efficacy of olanzapine versus perphenazine in patients with schizophrenia: results of multicenter, 18-week, double-blind clinical trial].

Jarema M, Olajossy M, Chrzanowski W, Araszkiewicz A, Landowski J, Rybakowski J, Bilikiewicz A, Bomba J, Debowska G.

Psychiatr Pol. 2003 Jul-Aug;37(4):641-55. Polish.

PMID:
14560493
9.

Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol.

Keefe RS, Seidman LJ, Christensen BK, Hamer RM, Sharma T, Sitskoorn MM, Lewine RR, Yurgelun-Todd DA, Gur RC, Tohen M, Tollefson GD, Sanger TM, Lieberman JA.

Am J Psychiatry. 2004 Jun;161(6):985-95.

PMID:
15169686
10.

[Prescription of olanzapine in children and adolescent psychiatric patients].

Frémaux T, Reymann JM, Chevreuil C, Bentué-Ferrer D.

Encephale. 2007 Mar-Apr;33(2):188-96. Review. French.

PMID:
17675914
11.
13.
14.

Olanzapine treatment of residual positive and negative symptoms.

Buchanan RW, Ball MP, Weiner E, Kirkpatrick B, Gold JM, McMahon RP, Carpenter WT Jr.

Am J Psychiatry. 2005 Jan;162(1):124-9.

PMID:
15625210
15.

Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia.

Möller HJ, Riedel M, Jäger M, Wickelmaier F, Maier W, Kühn KU, Buchkremer G, Heuser I, Klosterkötter J, Gastpar M, Braus DF, Schlösser R, Schneider F, Ohmann C, Riesbeck M, Gaebel W.

Int J Neuropsychopharmacol. 2008 Nov;11(7):985-97. doi: 10.1017/S1461145708008791. Epub 2008 May 9.

PMID:
18466670
16.

A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis.

Crespo-Facorro B, Pérez-Iglesias R, Ramirez-Bonilla M, Martínez-García O, Llorca J, Luis Vázquez-Barquero J.

J Clin Psychiatry. 2006 Oct;67(10):1511-21.

PMID:
17107241
17.

Belgian Schizophrenia Outcome Survey - results of a 2-year naturalistic study in patients stabilised on monotherapy with olanzapine, risperidone or haloperidol.

Peuskens J, Gillain B, De Graeve D, Van Vleymen B, Albert A.

Eur Psychiatry. 2009 Apr;24(3):154-63. doi: 10.1016/j.eurpsy.2008.11.002. Epub 2008 Dec 31.

PMID:
19118983
18.

Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder.

Krakowski MI, Czobor P, Citrome L, Bark N, Cooper TB.

Arch Gen Psychiatry. 2006 Jun;63(6):622-9.

PMID:
16754835
19.

Effectiveness and safety of olanzapine in the treatment of schizophrenia among Asian patients switching from conventional antipsychotics.

Lu Z, Hu J, Chen CK, Lan TH, Diokno GL Jr, Lee BY, McElroy H, Harrison G, Ang Q.

Prog Neuropsychopharmacol Biol Psychiatry. 2007 Jan 30;31(1):32-40. Epub 2006 Jul 14.

PMID:
16843580
20.

Quality of life and subjective well-being during treatment with antipsychotics in out-patients with schizophrenia.

Wehmeier PM, Kluge M, Schneider E, Schacht A, Wagner T, Schreiber W.

Prog Neuropsychopharmacol Biol Psychiatry. 2007 Apr 13;31(3):703-12. Epub 2007 Jan 16.

PMID:
17289237
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk